Market revenue in 2021 | USD 323.4 million |
Market revenue in 2028 | USD 713.3 million |
Growth rate | 12% (CAGR from 2021 to 2028) |
Largest segment | Commercialized |
Fastest growing segment | Commercialized |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Research, Commercialized |
Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 50.9% in 2021. Horizon Databook has segmented the Germany t-cell therapy market based on research, commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
In September 2018, the Department of Hematology, Oncology and Rheumatology of Heidelberg University Hospital was the first German center to provide patients with CAR T-cell therapy. Post EU approval of Kymriah in August 2018 for the treatment of B-cell ALL in young adults & children, the drug received orphan drug status in Germany for relapsed large B-cell lymphoma patients.
In Germany, the launch price of a drug is determined by the manufacturer for a year, while the Health Technology Assessment (HTA) and GKV-Spitzenverband (GKV-SV), a payer group, negotiate a price and reimbursement procedures are completed. According to a press release by Novartis, single hospitals are eligible to negotiate remuneration with payers for costs associated with use of Kymriah as a new treatment option under the NUB system framework.
For 2019, Kymriah was granted the NUB status 1, indicating that the drug met the criteria for hospital-individual NUB agreements. In Germany, the list price of Kymriah is set at USD 371,000, which is subject to negotiations and cost benefit assessments with payers.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany t-cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Germany t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account